medigraphic.com

2018, Number 1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2018; 56 (1)

Adverse cutaneous reactions to drugs

Suástegui-Rodríguez I, Campos-Jiménez KI, Domínguez-Cherit J, Méndez-Flores S

Language: Spanish
References: 42
Page: 64-70
PDF size: 280.54 Kb.


ABSTRACT

Adverse cutaneous reactions to drugs are any undesirable change in the structure or function of the skin. These are among the adverse side effects to common drugs. The most commonly implicated drugs are antibiotics and anticonvulsants. Cutaneous clinical manifestations are diverse ranging from mild or moderate reactions, such as urticaria and maculopapular rash, to severe cutaneous adverse reactions (SCAR), which are known due to their high morbidity and mortality (among these: Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). The clinical pattern, etiology, prognosis and treatment differ among these skin reactions, which is why it is necessary a clear diagnosis based on a comprehensive clinical examination, skin biopsy, and specific laboratory tests. The therapeutic options depend on the clinical diagnosis. For all reactions, a symptomatic and adequate supportive therapy is necessary; in some cases, a systemic immunomodulatory therapy can be useful.


REFERENCES

  1. World Health Organization (WHO). Tecnichal Report Series No 498: International Drug Monitoring, The Role of National Centers. Geneva, Switzerland: WHO; 1972.

  2. Wintroub BU, Stern R. Cutaneous drug reactions: pathogenesis and clinical classification. J Am Acad Dermatol. 1985 Aug;13(2 Pt 1):167-79.

  3. Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol. 2008;53(1):2-8.

  4. Qayoom S, Bisati S, Mazoor S, Sameem F, Khan K. Adverse cutaneous drug reactions—a clino-demographic study in tertiary care teaching hospital of the Kashimir Valley, India. Arch Iran Med. 2015 Apr;18(4):228-33.

  5. Hernández-Salazar A, Vega-Memije E, Hojyo-Tomoka MT. Epidemiología de las reacciones cutáneas adversas a fármacos, en el Servicio de Dermatología del Hospital General Dr Manuel Gea González. Dermatología Rev Mex. 2011;55(6):327-33. Disponible en http://www.medigraphic.com/pdfs/ derrevmex/rmd-2011/rmd116b.pdf

  6. Sharma VK, Sethuraman GG. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med. 1996 Jan-Mar;42(1):15-22.

  7. Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. UK guidelines for the management of Stevens-Johnson síndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg. 2016 Jun;69(6):e119-e153.

  8. Charli-Joseph Y, Cruz-Fuentes C, Orozco-Topete R. Incidence of adverse cutaneous drug reactions in a Mexican sample: an exploratory study on their association to tumour necrosis factor alpha TNF2 allele. J Eur Acad Dermatol Venereol. 2009 Jul;23(7):788-92.

  9. odiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Shear NH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015 Dec;16(6):475-93.

  10. Knowles S, Shear N. Clinical risk management of Stevens- Johnson syndrome/toxic epidermal necrolysis spectrum. Dermatol Ther. 2009 Sep-Oct;22(5):441-51.

  11. Schwartz R, McDonough P, Lee B. Toxic epidermal necrolysis. Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013 Aug;69(2):173.e1-13; quiz 185-6.

  12. Clonje E, Brenn T, Lazar A, McKee PH. McKee’s Pathology of the Skin with Clinical correlations. 4th ed. USA: Elsevier; 2012.

  13. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau J, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008 Jan;58(1):33-40.

  14. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolym- phoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996; 15:250-7.

  15. Picard D, Janela B, Descamps V, D’Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010; 2:46ra62.

  16. Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157:934.

  17. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013; 169:1071.

  18. Lin IC, Yang HC, Strong C, Yang CW, Cho YT, Chen KL, et al. Liver injury in patients with DRESS: A clinical study of 72 cases. J Am Acad Dermatol. 2015; 72:984.

  19. Chen YC, Chang CY, Cho YT. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013; 68(3):459-65.

  20. Chi MH, Hui RC, Yang CH, Lin JY, Lin YT, Ho HC, et al. Histopathological analysis and clinical correlation of drug reaction with eosinophilia and systemic symptoms (DRESS). Br J Dermatol. 2014 Apr;170 (4):866-73.

  21. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010 Dec;146(12):1373-9.

  22. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007 Nov;157(5):989-96.

  23. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127:1333-8.

  24. Birnie AJ, Litlewood SM. Acute generalized exanthematous pustulosis does not always have a drugrelated cause. Br J Dermatol. 2008 Aug;159(2):492-3.

  25. Kabashima R, Sugita K, Sawada Y, Hino R, Nakamura M, Tokura Y . Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Eur Acad Dermatol Venereol. 2011 Apr;25(4):485-8.

  26. Schmid S, Kuechler PC, Britschgi M, Steiner UC, Yawalkar N, Limat A, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol. 2002 Dec;161(6): 2079-86.

  27. Navarini AA, Simpson MA, Borradori L, Yawalkar N, Schlapbach C . Homozygous missense mutation in IL36RN in generalized pustular dermatosis with intraoral involvement compatible with both AGEP and generalized pustular psoriasis. JAMA Dermatol. 2015 Apr;151(4):452-3.

  28. Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol. 2010 Jul-Aug;20(4):425-33.

  29. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):291-6.

  30. Meneses MS, Copparoni C, Samper A, Mendez D, Valdemoros P. Pustulosis exántematica aguda generalizada: Presentación de un caso y revisión de la literatura. Rev Argent Dermatol. [Internet]. 2012 Mar;93(1). Disponible en http://www.scielo.org.ar/ scielo.php?script=sci_arttext&pid=S1851300X2012 000100002&lng=es [Consultado el 11 de septiembre de 2016].

  31. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA- 2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014; 69: 868-87.

  32. Hennino A, Bérard F, Guillot I, Saad N, Rozières A, Nicolas JF. Pathophysiology of Urticaria. Clin Rev Allergy Immunol. 2006 Feb;30(1):3-11.

  33. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986 Dec 26;256(24):3358-63.

  34. Spoerl D, Scherer K, Tyndall A. Aspects of allergy in rheumatology. Clin Exp Rheumatol. 2011 May-Jun;29(3):560-6.

  35. Schneider CH,De Weck AL. A new chemical aspect of penicillin allergy:the direct reaction of penicillin with epsilon-amino-groups. Nature. 1965 Oct 2;208 (5005):57-9.

  36. Justiniano H, Berlingeri-Ramos AC, Sánchez JL. Pattern analysis of druginduced skin diseases. Am J Dermatopathol. 2008 Aug;30(4):352-69.

  37. Pincelli C, Pignatti M, Borroni R. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Exp Dermatol. 2009 Apr;18(4): 337-49.

  38. Pincelli C, Pignatti M, Borroni R. Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy. Exp Dermatol. 2009 Apr;18(4): 337-49.

  39. Mongey, AB, Hess E. Drug insight: autoinmune effects of medications-what’s new? Nat Clin Pract Rheumatol. 2008 Mar;4(3):136-44.

  40. Dedeoglu F. Drug-induced autoimmunity. Curr Opin Rheumatol. 2009 Sep;21(5):547-51.

  41. Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun. 2014 Feb-Mar;48-49:66-72.

  42. Ichihara A, Wang Z, Jinnin M, Izuno Y, Shimozono N, Yamane K, et al. Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions. J Allergy Clin Immunol. 2014 Apr;133(4): 1065-74.




2020     |     www.medigraphic.com